NuPathe (PATH)

Add to Watchlists Create an Alert
3.17 +0.06  +1.93%   NASDAQ May 24, 8:00PM BATS Real time Currency in USD

NuPathe SG&A Expense Quarterly:

2.552M for Dec. 31, 2012
View Full Chart

NuPathe SG&A Expense Quarterly Chart

    NuPathe Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 2.552M
    Sept. 30, 2012 3.525M
    June 30, 2012 2.42M
    March 31, 2012 2.387M
    Dec. 31, 2011 1.906M
    Sept. 30, 2011 3.01M
    June 30, 2011 2.53M
    March 31, 2011 1.97M
       
    Dec. 31, 2010 1.634M
    Sept. 30, 2010 1.32M
    June 30, 2010 0.945M
    March 31, 2010 0.873M
    Dec. 31, 2009 0.7572M
    Sept. 30, 2009 0.8348M
    June 30, 2009 0.7539M
    March 31, 2009 0.7963M

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    PATH SG&A Expense Quarterly Benchmarks

    Companies
    Cadence Pharmaceuticals 21.64M
    Cytori Therapeutics 6.265M
    ARCA biopharma 0.889M

    PATH SG&A Expense Quarterly Rankings

    Overall 46th percentile
    4060 of 7600
    Sector 33rd percentile
    432 of 653 in Healthcare
    Industry 45th percentile
    130 of 238 in Biotechnology

    PATH SG&A Expense Quarterly Range, Past 5 Years

    Minimum 0.7539M Jun 2009
    Maximum 3.525M Sep 2012
    Average 1.763M